Joel Dudley

SymphonyAI Sensa LLC develops interactive analysis and visualization software. Its technology is used to discover new drug therapies, uncover the causes of diseases, root out financial fraud, accelerate energy exploration, discover customer segmentation and complement other Big Data solutions. The company was founded by Gurjeet Singh, Gunnar Carlson and Harlan Sexton in 2008 and is headquartered in Menlo Park, CA.

Innovation Endeavors LLC (Innovation Endeavors) is a venture capital firm founded in 2010 by Dror Berman and Eric E. Schmidt. The firm is headquartered in Palo Alto, California.

NuMedii, Inc. discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies. Its Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The firm translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. The company was founded by Gini Deshpande, Joel Dudley and Atul J. Butte in 2008 and is headquartered in Palo Alto, CA.

Scientia Ventures LLC (Scientia Ventures) is a venture capital firm founded in 2006 by Jonathan Finn. The firm is headquartered in New York.

Concord Health Partners LLC (Concord Health Partners) is a venture capital firm founded in 2017 by Joseph Swedish and James Olsen. The firm headquartered in Summit, New Jersey.

OrphAI Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in matching drugs to diseases and identifying the care for individual patients using Guardian Angel Artificial Intelligence algorithm. The company was founded by Tian Xu, Jonathan M. Rothberg and Henri S. Lichenstein in 2013 and is headquartered in Guilford, CT.

Silverware Software LLC develops mobile applications.

The American company was founded by Nick Johnson, Cheng Zhang, and Marcel van der Brug, with Cheng Zhang serving as the CEO since incorporation. Character Biosciences is focused on developing therapies for ophthalmic and other progressive polygenic diseases. The company has developed a platform that integrates genomics with longitudinal clinical data to select drug targets and match therapies to the right patients. Currently, Character Biosciences is advancing two lead drug discovery programs through preclinical development for dry age-related macular degeneration.